LUCA2 and Antibodies That Bind Thereto

Abstract

The invention provides the identification and characterization of disease and cancer-associated antigen, LUCA2. The invention also provides a family of monoclonal antibodies that bind to antigen LUCA2, methods of diagnosing and treating various human cancers and diseases that express LUCA2.

1 . A method of treating cancer in an individual comprising administering to said individual an amount of a composition sufficient to inhibit the growth of a cancer cell of said cancer in said individual, wherein said composition comprises a substantially purified immunoglobulin polypeptide or an antigen-binding fragment thereof associated with a chemotherapeutic agent, and wherein:
 (A) said substantially purified immunoglobulin polypeptide or antigen-binding fragment thereof specifically binds to an epitope that is specifically bound by the anti-LUCA2 antibody produced by the hybridoma having ATCC Deposit No. PTA-5068, wherein said epitope is expressed on normal neutrophils and on LNCaP prostate carcinoma cells; and   (B) said cancer cell is selected from the group consisting of a cancer cell from: an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, a bladder cancer, a bone cancer, a brain or spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumor, a cervical cancer, a chondrosarcoma, a dhordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome cell, a neuroblastoma, a neuroendocrine tumor, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer cell, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious unveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.   
     
     
         2 . The method of  claim 1 , wherein said composition delivers said chemotherapeutic agent to said cancer cell. 
     
     
         3 . The method of  claim 2 , wherein said chemotherapeutic agent is delivered into said cancer cell. 
     
     
         4 . The method of  claim 1 , wherein said substantially purified immunoglobulin polypeptide is the anti-LUCA2 antibody produced by the hybridoma ATCC No. PTA-5068 or progeny thereof. 
     
     
         5 . The method of  claim 1 , wherein said substantially purified immunoglobulin polypeptide is an anti-LUCA2 antibody. 
     
     
         6 . The method of  claim 5 , wherein the anti-LUCA2 antibody is a monoclonal antibody expressed by hybridoma ATCC No. PTA# 5068 or by a progeny thereof that produces the anti-LUCA2 antibody produced by hybridoma ATCC Deposit No. PTA-5068. 
     
     
         7 . The method of  claim 1 , wherein said substantially purified immunoglobulin polypeptide is an antigen-binding fragment of an anti-LUCA2 antibody. 
     
     
         8 . The method of  claim 7 , wherein the anti-LUCA2 antibody is a monoclonal antibody expressed by hybridoma ATCC No. PTA# 5068 or by a progeny thereof that produces the anti-LUCA2 antibody produced by hybridoma ATCC Deposit No. PTA-5068. 
     
     
         9 . The method of  claim 1 , wherein said cancer cell is a cancer cell of a breast cancer. 
     
     
         10 . The method of  claim 1 , wherein said cancer cell is a cancer cell of a lung cancer. 
     
     
         11 . The method of  claim 1 , wherein said cancer cell is a cancer cell of an ovarian cancer. 
     
     
         12 . The method of  claim 1 , wherein said cancer cell is a cancer cell of a pancreatic cancer. 
     
     
         13 . The method of  claim 1 , wherein said cancer cell is a cancer cell of a colon cancer. 
     
     
         14 . The method of  claim 1 , wherein said cancer cell is a cancer cell of a kidney cancer. 
     
     
         15 . The method of  claim 1 , wherein said cancer cell is a cancer cell of a prostate cancer. 
     
     
         16 . The method of  claim 1 , wherein said cancer cell is a cancer cell of a stomach cancer. 
     
     
         17 . The method of  claim 1 , wherein said chemotherapeutic agent is a radioactive molecule. 
     
     
         18 . The method of  claim 1 , wherein said chemotherapeutic agent is a cytotoxic agent.